<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004200</url>
  </required_header>
  <id_info>
    <org_study_id>AG-3340-019</org_study_id>
    <secondary_id>CDR0000067443</secondary_id>
    <secondary_id>MCC-12151</secondary_id>
    <secondary_id>MDA-DM-99254</secondary_id>
    <secondary_id>MSKCC-99116</secondary_id>
    <nct_id>NCT00004200</nct_id>
  </id_info>
  <brief_title>Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <official_title>A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in Combination With Temozolomide Following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      RATIONALE: Prinomastat may stop the growth of glioblastoma multiforme by stopping blood flow&#xD;
      to the tumor. Drugs used in chemotherapy stop tumor cells from dividing so they stop growing&#xD;
      or die.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of prinomastat plus&#xD;
      temozolomide in treating patients who have newly diagnosed glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the one year survival rate and progression free survival of patients&#xD;
      with newly diagnosed glioblastoma multiforme treated with prinomastat (AG3340) or placebo and&#xD;
      temozolomide following radiotherapy. II. Compare the safety of these regimens in these&#xD;
      patients. III. Compare the quality of life in these patients on these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study. Patients&#xD;
      receive oral prinomastat or placebo twice daily in combination with oral temozolomide daily&#xD;
      on days 1-5. Treatment repeats every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <primary_completion_date type="Actual">January 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prinomastat</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Newly diagnosed glioblastoma multiforme Must have completed all&#xD;
        appropriate subtotal or total surgical procedures (surgical biopsy alone not eligible) Must&#xD;
        have received prior external beam radiotherapy No multifocal glioblastoma multiforme No&#xD;
        radiographic disease progression during post surgical radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Karnofsky 70-100% Life&#xD;
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not&#xD;
        specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified&#xD;
        Endocrine therapy: Stable steroid therapy for at least 2 weeks prior to study Radiotherapy:&#xD;
        See Disease Characteristics No prior interstitial brachytherapy or radiosurgery Surgery:&#xD;
        See Disease Characteristics No prior radiosurgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Collier</last_name>
    <role>Study Chair</role>
    <affiliation>Agouron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Agouron Pharmaceuticals, Inc.</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>January 21, 2000</study_first_submitted>
  <study_first_submitted_qc>May 24, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2004</study_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Prinomastat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

